<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594435</url>
  </required_header>
  <id_info>
    <org_study_id>18-000963</org_study_id>
    <secondary_id>R01AA026190</secondary_id>
    <nct_id>NCT03594435</nct_id>
  </id_info>
  <brief_title>Ibudilast for the Treatment of Alcohol Use Disorder</brief_title>
  <official_title>A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>MediciNova</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a double-blind, placebo-controlled randomized clinical trial of IBUD (50mg BID)
      for the treatment of Alcohol Use Disorder (AUD). Eligible participants will undergo a 12-week
      medication treatment period and 5 in-person visits over 16 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design consists of a 12-week, double-blind, placebo-controlled randomized clinical
      trial of IBUD (50mg BID) for the treatment of Alcohol Use Disorder (AUD). The investigators
      will randomize 132 treatment-seekers with current AUD over the course of 4 years. As a
      behavioral support platform, all participants will complete the NIAAA-developed and
      computer-delivered program &quot;Take Control&quot; during the study. Participants will complete
      telephone screening, followed by in-person eligibility assessment, a physical exam for
      medical eligibility, randomization to study medication or matched placebo, and in-person
      follow-up visits at 4, 8, and 12 weeks of treatment. TLFB assessment of drinking outcomes
      will also occur by telephone on weeks 2, 6, and 10. A final safety check visit will occur on
      week 16, consisting of repeated clinical labs and ECG.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two-Arm, Randomized, Double-Blind, Placebo-Controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent heavy drinking days</measure>
    <time_frame>12 week-treatment period</time_frame>
    <description>Heavy drinking days defined as 5+ drinks for men and 4+ for women</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drinks per day</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>secondary alcohol consumption endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drinks per drinking day</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>secondary alcohol consumption endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent days abstinent</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>secondary alcohol consumption endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent subjects with no heavy drinking days</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>secondary alcohol consumption endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent subjects abstinent</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>secondary alcohol consumption endpoint</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Depressive Symptomatology</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>Responses from Beck Depression Inventory II (BDI-II) will be used to test this outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Neuroinflammation</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>Blood levels of proinflammatory markers</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Ibudilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg delayed-release capsules, target dose 50mg BID (5 x 10mg capsules twice daily) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matched to experimental drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibudilast</intervention_name>
    <description>targets neurotrophin signaling and neuroimmune function</description>
    <arm_group_label>Ibudilast</arm_group_label>
    <other_name>Pinatos</other_name>
    <other_name>MN-166</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>matched to active drug, ibudilast</description>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be between the ages of 18 and 65

          2. Meet current (i.e., past 12 months) DSM-5 diagnostic criteria for alcohol use disorder
             moderate or severe

          3. Be treatment-seeking for AUD

          4. Report drinking at least 28 drinks per week if male (21 drinks per week if female) in
             the 28 days prior to consent

        Exclusion Criteria:

          1. Have a current (last 12 months) DSM-5 diagnosis of substance use disorder for any
             psychoactive substances other than alcohol and nicotine

          2. Have a lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any psychotic
             disorder

          3. Have a positive urine screen for narcotics, amphetamines, or sedative hypnotics;

          4. Have clinically significant alcohol withdrawal symptoms as indicated by a score ≥ 10
             on the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-R)

          5. Be pregnant, nursing, or planning to become pregnant while taking part in the study;
             and must agree to one of the following methods of birth control (if female), unless
             she or partner are surgically sterile:

               -  Oral contraceptives

               -  Contraceptive sponge

               -  Patch

               -  Double barrier

               -  Intrauterine contraceptive device

               -  Etonogestrel implant

               -  Medroxyprogesterone acetate contraceptive injection

               -  Complete abstinence from sexual intercourse

               -  Hormonal vaginal contraceptive ring

          6. Have a medical condition that may interfere with safe study participation (e.g.,
             unstable cardiac, renal, or liver disease, uncontrolled hypertension or diabetes)

          7. Have AST, ALT, or GGT ≥ 3 times upper normal limit

          8. Have attempted suicide in the past 3 years and/or have had serious suicidal intention
             or plan in the past year

          9. Currently be on prescription medication that contraindicates use of IBUD, including
             alpha or beta agonists, theophylline, or other sympathomimetic

         10. Currently be on any medications for AUD or any psychotropic medications (e.g.,
             psychostimulants and benzodiazepines) with the exception of stable antidepressants
             (stable dose for ≥4 weeks)

         11. Have any other circumstances that, in the opinion of the investigators, compromises
             participant safety.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lara A. Ray, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Jenkins, MS</last_name>
    <phone>310-206-6756</phone>
    <email>jenkinsj@ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Addictions Laboratory</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Jenkins, MA</last_name>
      <phone>310-206-6756</phone>
      <email>raylab@psych.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Lara Ray, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Miotto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gang Li, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Irwin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Shoptaw, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>October 9, 2019</last_update_submitted>
  <last_update_submitted_qc>October 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Lara Ray, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ibudilast, treatment, medication development</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibudilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

